Explore the Potential with AI-Driven Innovation
Our detailed focused library is generated on demand with advanced virtual screening and parameter assessment technology powered by the Receptor.AI drug discovery platform. This method surpasses traditional approaches, delivering compounds of better quality with enhanced activity, selectivity, and safety.
We carefully select specific compounds from a vast collection of over 60 billion molecules in virtual chemical space. Our partner Reaxense helps in synthesizing and delivering these compounds.
Contained in the library are leading modulators, each labelled with 38 ADME-Tox and 32 physicochemical and drug-likeness qualities. In addition, each compound is illustrated with its optimal docking poses, affinity scores, and activity scores, giving a complete picture.
We employ our advanced, specialised process to create targeted libraries.
Fig. 1. The sreening workflow of Receptor.AI
Our strategy employs molecular simulations to explore an extensive range of proteins, capturing their dynamics both individually and within complexes with other proteins. Through ensemble virtual screening, we address proteins' conformational mobility, uncovering key binding sites at both functional regions and remote allosteric locations. This comprehensive investigation ensures a thorough assessment of all potential mechanisms of action, with the goal of discovering innovative therapeutic targets and lead molecules across across diverse biological functions.
Several key aspects differentiate our library:
partner
Reaxense
upacc
P01148
UPID:
GON1_HUMAN
Alternative names:
Progonadoliberin I
Alternative UPACC:
P01148; A0AVP0
Background:
Progonadoliberin-1, also known as Progonadoliberin I, plays a crucial role in human physiology by stimulating the secretion of gonadotropins, including luteinizing and follicle-stimulating hormones. These hormones are pivotal for reproductive health, influencing both the male and female reproductive systems.
Therapeutic significance:
The protein is directly linked to Hypogonadotropic hypogonadism 12 with or without anosmia, a condition marked by delayed or absent sexual maturation due to low gonadotropin levels. Understanding Progonadoliberin-1's function could lead to novel treatments for this disorder, enhancing reproductive health and quality of life for affected individuals.